Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Net Equity Issued and Repurchased (2021 - 2025)

Invivyd's (IVVD) quarterly Net Equity Issued and Repurchased came in at $10.9 million in Q4 2025, up 33962.5% on a YoY basis from N/an in Q4 2024, and up 13874.36% quarter-over-quarter from $78000.0 in Q2 2025.

Analysis

Invivyd (IVVD) Net Equity Issued and Repurchased (2021 - 2025) Analysis & Trends

Invivyd (IVVD) has reported Net Equity Issued and Repurchased for 5 consecutive years, with $10.9 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Net Equity Issued and Repurchased rose 33962.5% year-over-year to $10.9 million; the trailing twelve-month figure through Dec 2025 stood at $11.1 million (up 4856.95% YoY), and the FY2025 full-year result was $254000.0, up 13.9% from the prior year.
  • Net Equity Issued and Repurchased rose to $10.9 million in Q4 2025 per IVVD's latest filing, from $78000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $10.9 million in Q4 2025 and bottomed at -$101000.0 in Q3 2021.
  • Historically, Net Equity Issued and Repurchased has averaged $832357.1 across 5 years, with a median of $66000.0 in 2023.
  • The sharpest annual moves came in 2023 and 2025: Net Equity Issued and Repurchased plunged 63.33% in 2023, then surged 33962.5% in 2025.
  • Over 5 years, Net Equity Issued and Repurchased stood at -$101000.0 in 2021, then jumped by 218.81% to $120000.0 in 2022, then slumped by 63.33% to $44000.0 in 2023, then dropped by 27.27% to $32000.0 in 2024, then soared by 33962.5% to $10.9 million in 2025.
  • According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $10.9 million, $78000.0, and $44000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn -
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 9.00 Mn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 49.20 Mn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn -
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn -
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 10.90 Mn
Jun 30, 2025 78,000.00
Mar 31, 2025 44,000.00
Dec 31, 2024 32,000.00
Sep 30, 2024 27,000.00
Jun 30, 2024 75,000.00
Mar 31, 2024 89,000.00
Dec 31, 2023 44,000.00
Sep 30, 2023 57,000.00
Jun 30, 2023 56,000.00
Mar 31, 2023 83,000.00
Dec 31, 2022 120,000.00
Sep 30, 2022 149,000.00
Sep 30, 2021 -101,000.00